Literature DB >> 6309680

Effects of anti-transferrin receptor antibodies on growth of normal and malignant myeloid cells.

R Taetle, J M Honeysett, I Trowbridge.   

Abstract

The effects of three monoclonal antibodies (B3/25, 43/31, and 42/6) reactive with human transferrin (Tf) receptors on growth of normal and malignant myeloid cells were examined using in vitro culture techniques. When added directly to cultures, all three antibodies caused dose-dependent inhibition of normal granulocyte/macrophage progenitor (CFU-GM) growth. Monoclonal antibody 42/6 was by far the most potent of the three, with an ID50 of less than 5 micrograms/ml. Identical effects were seen on CFU-GM from three patients with chronic myelogenous leukemia. Growth of colonies from two myeloid leukemia cells lines (KG-I, HL60) was also inhibited by all three antibodies, and these cells were generally more sensitive than normal CFU-GM. Blast colony-forming cells from three patients with acute non-lymphocytic leukemia were relatively resistant to the antibodies, and CFU-GM from a patient with myeloid metaplasia were resistant (ID50 greater than 50 micrograms/ml) to 42/6. In liquid culture, growth of the leukemic cell lines was inhibited by saturating concentrations of the three antibodies, although in both liquid and colony culture recovery was seen even after exposure to antibody for periods of up to 72 h. Analysis of the cell-cycle status of these cells showed that the antibodies did not cause accumulation of cells in any particular phase of the cell cycle. Addition to cultures of large quantities of human Tf failed to reverse the inhibitory effects of the antibodies. Competitive binding studies on the leukemia cell lines showed that only 42/6 inhibited binding of Tf to its receptor, although all three antibodies inhibited cell growth. Addition of Fe chelate (as ferric nitriloacetic acid, FeNTA) failed to reverse the inhibitory effects of the antibodies on CFU-GM and HL60 cells, but had variable effects on KG-I cell growth. FeNTA fully reversed inhibitory effects of 42/6 on KG-I cells. We conclude that monoclonal antibodies to Tf receptors can inhibit growth of both normal and malignant myeloid cells. Overall, no selectivity for malignant vs normal cells is apparent, although malignant cells from one individual were more sensitive to colony inhibition by 43/31 monoclonal antibody than normal CFU-GM.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6309680     DOI: 10.1002/ijc.2910320314

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  21 in total

1.  Cellular adaptation to down-regulated iron transport into lymphoid leukaemic cells: effects on the expression of the gene for ribonucleotide reductase.

Authors:  C R Chitambar; J P Wereley; T Heiman; W E Antholine; W J O'brien
Journal:  Biochem J       Date:  2000-02-01       Impact factor: 3.857

2.  Inhibition of cell growth by monoclonal anti-transferrin receptor antibodies.

Authors:  J F Lesley; R J Schulte
Journal:  Mol Cell Biol       Date:  1985-08       Impact factor: 4.272

3.  Modification of transplasma membrane oxidoreduction by SV40 transformation of 3T3 cells.

Authors:  H Löw; F L Crane; C Grebing; M Isaksson; A Lindgren; I L Sun
Journal:  J Bioenerg Biomembr       Date:  1991-12       Impact factor: 2.945

4.  Molecular events contributing to cell death in malignant human hematopoietic cells elicited by an IgG3-avidin fusion protein targeting the transferrin receptor.

Authors:  Patrick P Ng; Gustavo Helguera; Tracy R Daniels; Simon Z Lomas; Jose A Rodriguez; Gary Schiller; Benjamin Bonavida; Sherie L Morrison; Manuel L Penichet
Journal:  Blood       Date:  2006-06-27       Impact factor: 22.113

5.  Selection and characterization of transferrin receptor mutants using receptor-specific antibodies.

Authors:  J Lesley; R Schulte
Journal:  Immunogenetics       Date:  1986       Impact factor: 2.846

6.  Activation of transferrin receptor 1 by c-Myc enhances cellular proliferation and tumorigenesis.

Authors:  Kathryn A O'Donnell; Duonan Yu; Karen I Zeller; Jung-Whan Kim; Frederick Racke; Andrei Thomas-Tikhonenko; Chi V Dang
Journal:  Mol Cell Biol       Date:  2006-03       Impact factor: 4.272

7.  Transferrin receptor expression by human bladder transitional cell carcinomas.

Authors:  G J Seymour; M D Walsh; M F Lavin; G Strutton; R A Gardiner
Journal:  Urol Res       Date:  1987

8.  Role of transferrin, Fe, and transferrin receptors in myeloid leukemia cell growth. Studies with an antitransferrin receptor monoclonal antibody.

Authors:  R Taetle; K Rhyner; J Castagnola; D To; J Mendelsohn
Journal:  J Clin Invest       Date:  1985-03       Impact factor: 14.808

Review 9.  Transferrin receptor-mediated endocytosis: a useful target for cancer therapy.

Authors:  Stephanie Tortorella; Tom C Karagiannis
Journal:  J Membr Biol       Date:  2014-02-27       Impact factor: 1.843

10.  Selection of cell lines resistant to anti-transferrin receptor antibody: evidence for a mutation in transferrin receptor.

Authors:  J F Lesley; R J Schulte
Journal:  Mol Cell Biol       Date:  1984-09       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.